LINZESS

This brand name is authorized in United States. It is also authorized in Hong Kong SAR China, Japan.

Active ingredients

The drug LINZESS contains one active pharmaceutical ingredient (API):

1	Linaclotide UNII N0TXR0XR5X - LINACLOTIDE
	Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans.
	Read more about Linaclotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LINZESS Capsule, gelatin coated	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	64139
JP	医薬品医療機器総合機構	2399017F1020
US	FDA, National Drug Code	0456-1201, 0456-1202, 0456-1203